Specific ICI regimens also appear to predispose to different neurologic phenotypes; for instance, anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) therapy is more commonly associated with myasthenic syndromes, while anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) agents are linked to meningitis and cranial neuropathies [32]. The gene discussed is PDCD1; the disease is infectious meningitis.